Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an Options trading signal: Unusual Options Activity and Options Screeners with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Atossa Therapeutics Inc (ATOS)

Atossa Therapeutics Inc (ATOS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 83,328
  • Shares Outstanding, K 129,171
  • Annual Sales, $ 0 K
  • Annual Income, $ -25,500 K
  • EBIT $ -33 M
  • EBITDA $ -33 M
  • 60-Month Beta 1.09
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.67
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.24
  • Most Recent Earnings $-0.07 on 11/12/25
  • Next Earnings Date 03/24/26
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical Instruments

Options Overview Details

View History
  • Implied Volatility 497.28% (+172.85%)
  • Historical Volatility 76.91%
  • IV Percentile 99%
  • IV Rank 76.06%
  • IV High 633.69% on 12/19/25
  • IV Low 63.91% on 07/10/25
  • Expected Move (DTE 4) 0.1700 (26.75%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 28
  • Volume Avg (30-Day) 264
  • Put/Call OI Ratio 0.08
  • Today's Open Interest 19,139
  • Open Int (30-Day) 18,020
  • Expected Range 0.4654 to 0.8054

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 4 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -0.07
  • Number of Estimates 2
  • High Estimate -0.07
  • Low Estimate -0.07
  • Prior Year -0.05
  • Growth Rate Est. (year over year) -40.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5510 +13.90%
on 12/31/25
0.7720 -18.70%
on 12/15/25
-0.1974 (-23.93%)
since 12/12/25
3-Month
0.5510 +13.90%
on 12/31/25
1.1500 -45.43%
on 10/13/25
-0.4524 (-41.89%)
since 10/10/25
52-Week
0.5510 +13.90%
on 12/31/25
1.2900 -51.35%
on 10/09/25
-0.2761 (-30.55%)
since 01/10/25

Most Recent Stories

More News
Atossa Therapeutics Receives FDA "Study May Proceed" Letter for (Z)-Endoxifen Investigational New Drug Application for Metastatic Breast Cancer

SEATTLE , Jan. 6, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical-stage biopharmaceutical company developing innovative medicines for unmet medical needs, today announced...

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Wins 2025 Clinical Trials Arena Research and Development Excellence Award in Precision Endocrine Therapy Category

Recognized for Advancing (Z)-Endoxifen, a Precision-Engineered Endocrine Therapy with Potential Across Multiple Breast Cancer and Rare Disease Settings

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Presents Four Clinical Trial Updates Highlighting (Z)-Endoxifen Research at the 2025 San Antonio Breast Cancer Symposium

Studies highlight findings regarding the potential use of (Z)-endoxifen to advance breast cancer treatment and risk reduction

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Receives FDA Rare Pediatric Disease Designation for (Z)-Endoxifen for Duchenne Muscular Dystrophy

Designation expands (Z)-Endoxifen program into rare pediatric neuromuscular disease and may qualify Atossa for a future Priority Review Voucher upon approval

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Announces Issuance of U.S. Patent Covering Enteric Oral (Z)-Endoxifen Formulations and Methods of Treating Patients Using (Z)-Endoxifen

New patent further strengthens global intellectual property estate supporting Atossa's lead program across the breast cancer spectrum and other hormone-driven conditions

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Details Accelerated FDA Strategy to Advance (Z)-Endoxifen Across Breast Cancer Continuum

Company positioned to pursue expedited regulatory pathways in metastatic, neoadjuvant, and risk-reduction settings

ATOS : 0.6493 (+0.65%)
Insilico Medicine and Atossa Therapeutics Publish AI-Driven Study in Nature Scientific Reports Identifying (Z)-Endoxifen as a Potential Therapeutic Candidate for Glioblastoma

CAMBRIDGE, Mass. , Dec. 2, 2025 /PRNewswire/ -- Insilico Medicine ("Insilico"), a global leader in AI-powered drug discovery, and Atossa Therapeutics ("Atossa") (Nasdaq: ATOS), a clinical-stage biopharmaceutical...

ATOS : 0.6493 (+0.65%)
Atossa Highlights Emerging Opportunity for (Z)-Endoxifen in Duchenne Muscular Dystrophy, Including Symptomatic Female Carriers, Following Peer-Reviewed Publication and Scientific Presentation

Published article outlines rationale for multi-pathway efficacy for (Z)-endoxifen in Duchenne Muscular Dystrophy (DMD) ; November scientific presentation to spotlight potential in Duchenne carrier–associated...

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Reports Third Quarter 2025 Financial Results and Provides a Corporate Update

Company reports progress to file planned IND for (Z)-endoxifen in mBC with CRO selection and streamlined development programs for potential 2026-NDA enabling activities, including a Type C meeting with...

ATOS : 0.6493 (+0.65%)
Atossa Therapeutics Announces Acceptance of Four Abstracts Highlighting (Z)-Endoxifen Research for Presentation at the 2025 San Antonio Breast Cancer Symposium

Studies highlight findings in the use of (Z)-endoxifen to advance breast cancer treatment and prevention

ATOS : 0.6493 (+0.65%)

Business Summary

Atossa Genetics Inc. is a healthcare company focused on the development and marketing of cellular and molecular diagnostic risk assessment products for breast cancer. The Company's diagnostic tests consist of medical devices which can collect fluid samples from the breast milk ducts. It is also conducting...

See More

Key Turning Points

3rd Resistance Point 0.7053
2nd Resistance Point 0.6872
1st Resistance Point 0.6662
Last Price 0.6493
1st Support Level 0.6271
2nd Support Level 0.6090
3rd Support Level 0.5880

See More

52-Week High 1.2900
Fibonacci 61.8% 1.0077
Fibonacci 50% 0.9205
Fibonacci 38.2% 0.8333
Last Price 0.6493
52-Week Low 0.5510

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar